Data Analysis and Evaluation of the Incidence of Life-threatening Ventricular Arrhythmias in Patients with Newly Diagnosed Cardiomyopathies of NICM or MI/CAD Origin PROTECTED from SCD by a WCD
Launched by HANNOVER MEDICAL SCHOOL · Mar 12, 2025
Trial Information
Current as of May 09, 2025
Completed
Keywords
ClinConnect Summary
SCD-PROTECT is an epidemiological, observational, multicenter study, evaluating the incidence of sudden cardiac arrest (SCA) / sudden cardiac death (SCD) in patients with reduced left ventricular ejection fraction (LVEF) due to newly diagnosed non-ischemic cardiomyopathy (NICM) or a myocardial infarction/coronary artery disease with intervention (MI/CAD). In the early phase (3 months) during up-titration of guideline-recommended therapy (GRMT) a wearable cardioverter defibrillator (WCD) can be indicated due to increased risk for SCA/SCD in these patients. The WCD provides continuous arrhyth...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects must be 18 years of age or older.
- • Subjects must be prescribed a WCD for a high risk of SCD.
- • Subjects must have been fitted with a WCD, and a baseline for ECG-analysis must have been established.
- • Subjects must have worn the WCD; time zero of inclusion is the activation of the ECG.
- • Subjects must have had a diagnosis of newly diagnosed NICM or MI/CAD with reduced LVEF as indication for WCD prescription.
- Exclusion Criteria:
- • No specific exclusion criteria will be applied.
About Hannover Medical School
Hannover Medical School (Medizinische Hochschule Hannover, MHH) is a leading academic medical institution in Germany, renowned for its commitment to innovative research and high-quality clinical care. Established in 1965, MHH specializes in a wide range of medical disciplines, with a strong focus on transplantation medicine, regenerative medicine, and personalized healthcare. The institution actively participates in clinical trials to advance medical knowledge and develop cutting-edge therapies, leveraging its state-of-the-art facilities and collaborative environment. With a dedicated team of researchers, clinicians, and support staff, Hannover Medical School aims to translate scientific findings into practical applications that improve patient outcomes and enhance the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hannover, , Germany
Patients applied
Trial Officials
Johann Bauersachs, MD
Principal Investigator
Hannover Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported